Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Did the first recruited patient get dosed in AD or just recruited for trial? Anyone?
AVXL enrolls First patient. Does that equal dosing of first patient?
Comparison: SQ projects FY18 adj eps of between .39-.41 but IIIV projects FY19 adj eps of between .79-.81c.. Do not miss IIIV.
News: SQ projects FY18 adj. eps between .42-.46c, IIIV projects FY19 adj eps between .79-.81c ! Own both payment systems.
According to last CC, Rett, AD and PD all trials to start in 2018. Will add more since bank CD pay me nothing.
Growth favorites remain SQ and IIIV. In fact, IIIV projects FY19 adj eps of between .79-.81c per share !
Looks like PYPL and IIIV best of breed. IIIV projects FY19 adj eps .79-.81c !!
Closer each day to Trial starts !
2:1 Split most likely. Jobs did last one in 2014. Whispers.
Here is some NICE math for PTIE;
8.8 million shares @ $1.15 + 8.8 million warrants to buy shares @ $1.25 leads to about 24 million outstanding shares for PTIE. That would raise 21 million in cash PLUS the 3 million + grant = 24 million in funds/cash as well. AXON for example with failure in ALzheimers has a Market cap of 250 million. So PTIE would need to trade at $10 for a MC of 250 million and their drug looks promising. The investors at $10.20 would make 9 dollars a share or 153 million in profit since they would be buying these 17 m shares at a avg cost of $1.20 including the warrants exercised. A $5 stock price would only be a 120 million market cap..This looks very inexpensive going into a MULTI BILLION dollar market in phase 2 this calendar year.
DESCRIPTION provided by applicant PTI is a novel compound with a novel target designed to treat and slow the progression of Alzheimerandapos s disease AD PTI works by binding extremely tightly to a particular site on filamin A FLNA a protein we recently demonstrated to be critical to beta amyloidandapos s toxicity Beta amyloid A exerts its toxic effects by binding and hijacking the a nicotinic acetylcholine receptor a nAChR disrupting its normal function and causing the signature tangles and plaques found in brains of AD patients We recently showed that this toxic signaling by A requires the help of FLNA which is recruited to interact with a nAChR when A binds this receptor A andapos s toxic signaling via a nAChR also impairs the function of two other receptors key to cognition memory and neuronal survival the NMDA receptor and the insulin receptor By disrupting the FLNA a nAChR association PTI prevents A andapos s toxic effects and restores normal function of these three receptors PTI also disrupts a similar association of FLNA with toll like receptor TLR a receptor responsible for releasing inflammatory cytokines hence PTI has a second function of blocking the inflammation noted in AD brain PTI has passed the Ames and hERG tests non GLP for mutagenicity and cardiac toxicity respectively It easily passes the blood brain barrier has an estimated oral bioavailability and has a reasonable half life for a drug candidate It was safe given orally for two months in mice We know the effective concentrations in brain from brain slice culture experiments PTI is ready to start the proposed IND enabling studies to ensure safety prior to a clinical trial In this proposal our Phase I work will include the non GLP dose selection studies more formal PK ADME work genotoxicity studies and the GLP validation of previously developed analytical and bioanalytical methods Barring unexpected toxicity in a dose range close to the anticipated therapeutic dose we will proceed to the Phase II scope of work GLP safety pharmacology and both week and chronic GLP toxicology studies that would support a first in human study as well as clinical trials in AD and an NDA PUBLIC HEALTH RELEVANCE There is currently no approved therapeutic for Alzheimerandapos s disease AD that can slow or halt the course of the disease PTI is a novel compound has been shown to alleviate multiple pathological features of AD in a mouse model of the disease as well as in postmortem brain tissue from AD patients including receptor dysfunctions inflammation and the hallmark plaques and tangles In this proposal we will complete the week and chronic GLP toxicology studies to ensure safety for a first in human clinical trial of PTI and to support clinical trials in AD and an eventual new drug application NDA
* Information listed above is at the time of submission. *
NIH grants millions to PTIE for a phase 2 study in Alzheimers this calendar year. Imo that is worth $8+
NIH grants PTIE millions for AD today. Is the government finally handing out grants for Alzheimers?
CC Highlights:
1. 25.8 million in cash enough funding for the next 24 months. Grants include Rhett Foundation to be covered during course of trial and Australian Government which can reimburse 40% of expense of the AD trial.
2. Rhett on track to start in current half of 2018.
3. Alzheimers trial, phase 2/3 will be 48 weeks and start in next few months
4. PD trial. phase 2 will measure cognitive and motor improvements and will be 14 weeks and start in next few months.
5, During Q and A Dr. Missling said trials should start in the next couple of months (different than a few months) and all should start in 2018.
6, Extensive use of genetic biomarkers in precision medicine in all 3 trials to support better trial results.
CNBC analyst on power lunch called ROKU earlier but recommends ORBC now.
Who will be asking questions on CC today? When will trials start in AD, PD and Rhett?
I would love to see Musk buy AVXL with its alzheimers and CNS pipeline.
Musk should but AVXL and take private at $30, could make billions.
BIIB down $40, if they buy AVXL imo Biogen runs to $500/share +. CEO would be the genius who stabilized AD and most CNS diseases. Their institutional shareholders would be very happy.
IF BIIB buys AVXL I think BIIB goes quickly to $500/share. Best results in Alzheimers I have seen and will be huge in all CNS diseases.
IQ will post bigger revenues than GRUB and they flew 25 points on earnings news !
NEWS: Super responders from AVXL and TORC.Look at stock gains today
AVXL and TORC with super responders but LOOK what it trading at today !
TORC just announced super responders too and look at that stock !! But not in Alzheimers , AVXL should be at 40.
What dates are the posters presented for AVXL?
TLRY and SEED my favorites !
One year Bank CD at 1% or AVXL for 1 year?
AVXL after I did my DD.
TLRY and SEED my favorites ! And going higher.
Breakouts: HUYA, IQ ,SOGO and BILI
Breakouts: IQ, HUYA, SOGO and BILI
Entering the hot SAAS market is worth $10 imo.
Coiled spring. So many catalysts that could open us above $10 one morning and never look back. Shorts realize they can make an unlimited amount by going long and only $3 by staying short and potential to lose everything as stock moves higher and higher. They probably shorted AMGN at $3 too at one time and now claim to be longs when they bought over 100.
Agree articles suggest a major move upward, this news and volume looks like the catalyst.
Great Find. Would FB also finance BBOX?
Shorts are screwed imo. Cantor will place in institutional hands that do not sell. The games are OVER !!!
Cantor is well known for getting stock positions for Institutions, you wont see any shares sold in the market. I have seen stocks skyrocket on other Cantor deals. I am stoked.
GOOG just announced on 2-20-18 they are expanding data centers, interesting ! But also many other social media giants as well, FB TWTR, ORCL etc. This is the hot place to be for BIIB.
$5+ tomorrow?
Remember caregivers and patients requested trial extension TWICE because of the amazing results on patients.. $35+
Missling and directors have a plan in place. If results help just 10% of patients approval is almost assured and helps millions and leads to billions $$ in CNS patients with its safe profile. Each news announcement now does not fall on deaf ears anymore.